Ionis provides update to development program evaluating anti-allergic drug PCSK9 for the treatment of hypercholesterolemia.

  • ION449 (AZD8233) met the first endpoint within the section 2 b Solano A examine of sufferers with excessive ldl cholesterol

  • ION449 won’t advance to Part 3 improvement based mostly on pre-set standards

Carlsbad, California.And the September 23, 2022 /PRNewswire/ — Ionis Prescription drugs, Inc. (Nasdaq: IONS) in the present day that the principle outcomes of the stage 2 b Solano The examine in hypercholesterolemic sufferers confirmed that 60 mg of ION449 (AZD8233) administered month-to-month achieved a statistically vital 62.3% (P < 0.001) discount in LDL-C ranges after 28 weeks in comparison with placebo, occasion finish level. ION449 was usually secure and well-tolerated on this examine. Nonetheless, these outcomes didn't meet the beforehand established efficacy standards and AstraZeneca determined to not immediate ION449 (AZD8233) to develop stage 3 hypercholesterolemia. AstraZeneca continues to research outcomes from Solano Examine to find out the subsequent steps of this system.

(PRNewsfoto/Ionis Pharmaceuticals, Inc.)

(PRNewsfoto/Ionis Prescription drugs, Inc.)

“Whereas the LDL-C reductions noticed in high-risk hypercholesterolemic sufferers taking the utmost statin remedy have been statistically vital and sturdy, these outcomes didn’t meet the standards for an AstraZeneca goal product profile to put money into a large-scale improvement program for the third stage,” Eugene SchneiderMD, govt vice chairman, chief medical improvement officer at Ionis. “AstraZeneca continues to be a priceless collaborator, and we stay up for working with them to develop many necessary packages.”

Round Solano

Solano (NCT04964557) was a placebo-controlled, double-blind, parallel stage 2 b A examine in 411 individuals with hyperlipidemia LDL-C of 70 mg/dL and <190 mg/dL on the utmost tolerated statin and/or ezetimibe. The first goals of this examine have been to guage the efficacy, security and tolerability of ION449 (AZD8233) compared to placebo.

About ION449

ION449 (AZD8233) without delay month-to-month dose by subcutaneous administration, is an investigational drug utilizing superior Ionis LIKnot-cshut antisense expertise platform (LICA). It’s designed to scale back plasma ranges of the protein proprotein convertase subtilisin/kexin sort 9 (PCSK9). PCSK9 is primarily concerned within the regulation of low-density lipoprotein ldl cholesterol. Genetic research have proven that people with lifelong low LDL-C resulting from decreased PCSK9 perform have a considerably decreased danger of heart problems. Pharmacological inhibition of PCSK9 considerably lowers LDL-C. ION449 is designed to lower the liver’s manufacturing of PCSK9 and decrease the extent of LDL-C within the plasma, thus decreasing the chance of heart problems. AstraZeneca acquired the ION449 license from Ionis in 2015.

about excessive ldl cholesterol

Hypercholesterolemia, or excessive ranges of LDL-C within the blood, is a crucial danger issue for heart problems, and is the main reason behind loss of life worldwide. There’s a vital unmet medical want for stronger LDL-C reducing therapies in secondary prevention sufferers with roughly 50% who don’t obtain their therapy objectives regardless of taking HDL statins. It’s estimated that one in six sufferers with LDL-C >100mg/dL will expertise a second antagonistic cardiovascular occasion over a interval of roughly three years.

About Ionis Prescription drugs, Inc.

For greater than 30 years, Ionis has pioneered focused RNA remedy, pioneering new markets and altering requirements of care with its new hypoallergenic expertise. Ionis at the moment has three marketed medication and a serious late-stage pipeline highlighted by industry-leading cardiovascular and neurological franchises. Our scientific innovation started and continues with the information that sufferers rely on us, furthering our imaginative and prescient of turning into a number one and absolutely built-in biotechnology firm.

To be taught extra about Ionis, go to and observe us on Twitterionispharma.

Eunice’s forward-looking assertion

This press launch contains forward-looking statements relating to Ionis’ enterprise and the therapeutic and industrial prospects of Ionis applied sciences, ION449 and different merchandise in improvement. Any assertion describing Ionis’ goals, expectations, monetary or different expectations, intentions or beliefs is forward-looking and needs to be thought-about an announcement of danger. Such statements are topic to sure dangers and uncertainties, together with these referring to the influence that COVID-19 might have on our enterprise, together with however not restricted to, these referring to our industrial merchandise and medicines in our pipeline, specifically these related to them. The method of discovering, growing and advertising and marketing secure and efficient medicines to be used as human therapies, and in making an attempt to construct a enterprise round these medicines. Ionis’ forward-looking statements additionally embrace assumptions that, if by no means realized or substantiated, might trigger their outcomes to vary materially from these expressed or implied by such forward-looking statements.

Though Ionis’ forward-looking statements mirror the great religion judgment of its administration, these statements are based mostly solely on info and elements at the moment recognized by Ionis. In consequence, you’re cautioned to not place reliance on these forward-looking statements. These and different dangers associated to Ionis packages are described in extra element in Ionis annual report on Kind 10-Ok for the 12 months ended. December 31, 2021, and the latest quarterly file for Kind 10-Q, which is on file with the Securities and Alternate Fee. Copies of this and different paperwork can be found from the corporate.

On this press launch, until the context in any other case requires, “Ionis,” “the Firm,” “we,” “us,” and “us” check with Ionis Prescription drugs and its associates.

Ionis Prescription drugs® is a trademark of Ionis Prescription drugs, Inc.



View unique content material for multimedia obtain: -301631819.html

SOURCE Ionis Prescription drugs, Inc.